March 22, 2024Cancer Research

Targeting Chromatin Remodeling Protein SMARCA1 as Potential Therapy in Pediatric Rhabdomyosarcoma

View Full Paper

Ask AI

Bookmark

Genetic depletion of SMARCA1 disrupts sphere formation and suppresses cell migration in pediatric rhabdomyosarcoma models, diminishing overall cellular viability.
Phenotypic experiments demonstrate that SMARCA1 knockout in fusion-positive cell lines causes confluency loss upon trametinib treatment without normal recovery.
Findings indicate SMARCA1 interacts with HDAC2 to modulate chromatin remodeling in tumorigenesis; preclinical cell model requires further in vivo validation.

Authors

AAAshwaq K. AljabriIndependent Sector KHKatie E. HebronPurdue University West Lafayette YKYuliya KrigaFrederick National Laboratory for Cancer Research

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates SMARCA1 depletion impairs growth and sensitizes rhabdomyosarcoma cells to trametinib, highlighting a novel therapeutic target.

Cite This Study

Aljabri et al. (2024) studied this question.

synapsesocial.com/papers/68e72e40b6db6435876a84e9 https://doi.org/10.1158/1538-7445.am2024-1723

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates SMARCA1 depletion impairs growth and sensitizes rhabdomyosarcoma cells to trametinib, highlighting a novel therapeutic target.

Targeting Chromatin Remodeling Protein SMARCA1 as Potential Therapy in Pediatric Rhabdomyosarcoma

Key Points

Discussion

Implication

Cite This Study

Targeting Chromatin Remodeling Protein SMARCA1 as Potential Therapy in Pediatric Rhabdomyosarcoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider